News
XGN
4.260
-0.23%
-0.010
Weekly Report: what happened at XGN last week (0511-0515)?
Weekly Report · 5d ago
Exagen Earnings Call Highlights Growth Amid Key Risks
TipRanks · 05/13 00:39
Exagen (XGN) Q1 2026 Earnings Transcript
NASDAQ · 05/12 18:16
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
TipRanks · 05/12 15:15
Exagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
TipRanks · 05/12 12:35
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 05/12 12:06
Exagen (XGN) Receives a Buy from BTIG
TipRanks · 05/12 12:04
Exagen price target lowered to $8 from $9 at BTIG
TipRanks · 05/12 11:50
Exagen Price Target Cut to $8.00/Share From $9.00 by BTIG
Dow Jones · 05/12 10:59
Exagen Is Maintained at Buy by BTIG
Dow Jones · 05/12 10:59
BTIG Maintains Buy on Exagen, Lowers Price Target to $8
Benzinga · 05/12 10:49
Exagen’s Risk Profile Remains Unchanged: Stable Yet Persistent Exposures Keep Investors on Alert
TipRanks · 05/12 06:00
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time
Seeking Alpha · 05/12 05:31
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Liquidia Technologies (LQDA)
TipRanks · 05/11 18:40
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 05/11 17:05
Exagen reports Q1 EPS (17c), consensus (25c)
TipRanks · 05/11 16:09
Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M
TipRanks · 05/11 16:03
Exagen beats Q1 revenue estimates, reaffirms 2026 guidance
Reuters · 05/11 12:09
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 05/11 12:06
EXAGEN INC - MAINTAINS FY2026 REVENUE GUIDANCE OF $70 MLN TO $73 MLN
Reuters · 05/11 12:00
More
Webull provides a variety of real-time XGN stock news. You can receive the latest news about Exagen Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XGN
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.